CD274 and non-small cell lung carcinoma: Third, the 2016–2018 study period preceded both (a) clinical adoption of PD‐L1 testing in resected NSCLC and (b) modern adjuvant therapies (targeted agents/immunotherapy), preventing biomarker‐stratified survival analyses.